Silver Book Fact

Vaccines in development 2013

Fact image

Vaccines in development for 2013

Pharmaceutical Researchers and Manufacturers of America. Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines. Washington, D.C.: PhRMA; 2013. http://phrma.org/medicines-in-development-for-vaccines-2013

Reference

Title
Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines
Publisher
PhRMA
Publication Date
2013
Authors
Pharmaceutical Researchers and Manufacturers of America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.  
  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline